Zenarc Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 2.50 M
- Company Age 3 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth %
- Profit Growth -1546.81%
- Ebitda -450.71%
- Net Worth 5.76%
- Total Assets 478.40%
About Zenarc Pharmaceuticals
Zenarc Pharmaceuticals Private Limited (ZPPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 November 2021 (Three years and three months 16 days old ). Its registered office is in Mahabub Nagar, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M, as per Ministry of Corporate Affairs (MCA) records.
Ande Reddy and Andhe Sameera serve as directors at the Company.
Company Details
- Location
Mahabub Nagar, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U33302TG2021PTC156781
- Company No.
156781
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Nov 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Zenarc Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ande Reddy  | Director | 09-Nov-2021 | Current |
| Andhe Sameera | Director | 09-Nov-2021 | Current |
Financial Performance of Zenarc Pharmaceuticals.
Zenarc Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 1546.81% decrease in profit. The company's net worth moved up by a moderate rise of 5.76%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zenarc Pharmaceuticals?
In 2023, Zenarc Pharmaceuticals had a public holding of 40.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Dr. Prathibha Peoples Health Care Private LimitedAnde Reddy is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Zenarc Pharmaceuticals?
Zenarc Pharmaceuticals has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zenarc Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zenarc Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.